FIG 3.

(A) Dynamics of the CD39⁺ Tregs (FoxP3^high CD4⁺ T cells) after the administration of anti-CCR4-DT, low-dose IL-2-DT, and high-dose IL-2-DT. (B) Dynamics of the CD73⁺ Tregs after the administration of anti-CCR4-DT, low-dose IL-2-DT, and high-dose IL-2-DT. The y axes illustrate the frequency of CD39⁺ or CD73⁺ Tregs (%). (C and D) Dynamics of T cell immune activation, as illustrated by the levels of K_i-67 expression by the CD4⁺ (C) and CD8⁺ (D) T cells after administration of anti-CCR4-DT, low-dose IL-2-DT, and high-dose IL-2-DT. (E and F) Dynamics of T cell immune activation, as illustrated by the levels of CD38 and HLA-DR coexpression by the CD4⁺ (E) and CD8⁺ (F) T cells after administration of anti-CCR4-DT, low-dose IL-2-DT, and high-dose IL-2-DT. The y axes illustrate the frequency (%) of activated CD4⁺ or CD8⁺ T cells; the x axes illustrate the number of days post-DT administration. Different treatments are color-coded. A Friedman test was performed individually for each treatment, and P < 0.05 (boldface) values were considered significant.